Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival
Authors:
- Guilherme Freire Angotti CarraraGCGuilherme Freire Angotti Carrara
- Adriane Feijo EvangelistaAEAdriane Feijo Evangelista
- Cristovam Scapulatempo-NetoCSCristovam Scapulatempo-Neto
- Lucas Faria Abrahão-MachadoLALucas Faria Abrahão-Machado
- Maria Aparecida Azevedo Koike FolgueiraMFMaria Aparecida Azevedo Koike Folgueira
- René Aloisio da Costa VieiraRVRené Aloisio da Costa Vieira
- 20 September 2020
- journal article
- research article
- Published by Springer Nature in Breast Cancer
- Vol. 28 (2) , 307-320
Abstract
Background Non-metastatic locally advanced breast carcinoma (LABC) treatment involves neoadjuvant chemotherapy (NCT). We evaluated the association of clinical–pathological data and immunoexpression of hormone receptors, HER2 and Ki67, and new biomarkers, RPL37A, MTSS1 and HTRA1, with pathological complete response (PCR) or tumour resistance (stable disease or disease progression), disease-free survival (DFS) and cancer-specific survival (CSS). Methods This is a retrospective study of 333 patients with LABC who underwent NCT. Expression of MTSS1, RPL37A and HTRA1/PRSS11 was evaluated by immunohistochemistry in TMA slides. Cutoff values were established for low and high tumour expression. ROC plotter evaluated response to NCT. Chi-square test for factors related to PCR, and Kaplan–Meier test and Cox model for factors related to DFS and CSS were prformed. Results The mean follow-up was 70.0 months and PCR rate was 15.6%. At 120 months, DFS rate was 32.5% and CSS rate was 67.1%. In multivariate analysis, there was an association between: (1) necrosis presence, intense inflammatory infiltrate, ER absence, HER2 molecular subtype and high RPL3A expression with increased odds of PCR; (2) lymph node involvement (LNI), high Ki67, low RPL37A and high HTRA1 expression with increased risk for NCT non-response; (3) LNI, high proliferation, necrosis absence, low RPL37A and high HTRA1 expression with increased recurrence risk; (4) advanced LNI, ER negative tumours, high HTRA1, low RPL37A expression and desmoplasia presence with higher risk of cancer death. Conclusion RPL37A is a potential biomarker for response to NCT and for prognosis. Additional studies evaluating HTRA1 and MTSS1 prognostic value are needed.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2012/19642-0)
This publication has 39 references indexed in Scilit:
- Downregulation of Serine Protease HTRA1 Is Associated with Poor Survival in Breast CancerPLOS ONE, 2013
- Value of TP53 Status for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-AnalysisPLOS ONE, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- MTSS1 Overexpression Correlates with Poor Prognosis in Colorectal CancerJournal of Gastrointestinal Surgery, 2011
- The impact of Metastasis Suppressor-1, MTSS1, on oesophageal squamous cell carcinoma and its clinical significanceJournal of Translational Medicine, 2011
- Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant settingThe Breast, 2009
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancerActa Veterinaria Scandinavica, 2008
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000